Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 12, 2011, Pages 4997-5002

  Verstraeten, Valerie L R M ^a,b,c   Peckham, Lana A ^a   Olive, Michelle ^d   Capell, Brian C ^e   Collins, Francis S ^e   Nabel, Elizabeth G ^d,e   Young, Stephen G ^f   Fong, Loren G ^f   Lammerding, Jan ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antitumor; Cell division; Doughnut shaped nuclei; Nuclear envelope

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; LAMIN B; LAMIN B1; LONAFARNIB; MEVINOLIN; PERICENTRIN; PRAVASTATIN; PROTEASOME; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANEUPLOIDY; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIVISION; CELL NUCLEUS; CELL PROLIFERATION; CENTROSOME; CENTROSOME SEPARATION DEFECT; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; KARYOKINESIS; MITOSIS; MORNING DOSAGE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTIGENS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CENTROSOME; HEP G2 CELLS; HUMANS; LAMIN TYPE B; MICE; MICE, TRANSGENIC; MITOSIS; MITOTIC SPINDLE APPARATUS; PROGERIA; PROTEIN PRENYLATION;

MUS;

EID: 79953185053     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1019532108     Document Type: Article

References (35)

1. Sousa SF, Fernandes PA, Ramos MJ (2008) Farnesyltransferase inhibitors: A detailed chemical view on an elusive biological problem. Curr Med Chem 15:1478-1492. (Pubitemid 351997780)
2. Cox AD, Der CJ (2002) Ras family signaling: Therapeutic targeting. Cancer Biol Ther 1: 599-606.
3. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
4. Fong LG, et al. (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311:1621-1623.
5. Yang SH, et al. (2006) A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 116: 2115-2121. (Pubitemid 44162320)
6. Capell BC, et al. (2008) A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA 105:15902-15907.
7. Glynn MW, Glover TW (2005) Incomplete processing of mutant lamin A in Hutchinson- Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 14:2959-2969. (Pubitemid 41535461)
8. Toth JI, et al. (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 102: 12873-12878. (Pubitemid 41279458)
9. Verstraeten VL, et al. (2006) Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation. Hum Mol Genet 15: 2509-2522. (Pubitemid 44288703)
10. Sinensky M, Beck LA, Leonard S, Evans R (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265: 19937-19941. (Pubitemid 120013953)
11. Varela I, et al. (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14: 767-772.
12. Mayer TU, et al. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971-974.
13. Rauch A, et al. (2008) Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science 319:816-819. (Pubitemid 351225872)
14. Doxsey SJ, Stein P, Evans L, Calarco PD, Kirschner M (1994) Pericentrin, a highly conserved centrosome protein involved in microtubule organization. Cell 76:639-650. (Pubitemid 24070649)
15. Putkey FR, et al. (2002) Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 3:351-365.
16. Schafer-Hales K, et al. (2007) Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 6:1317-1328. (Pubitemid 46711995)
17. Moynihan KL, Pooley R, Miller PM, Kaverina I, Bader DM (2009) Murine CENP-F regulates centrosomal microtubule nucleation and interacts with Hook2 at the centrosome. Mol Biol Cell 20:4790-4803.
18. Hussein D, Taylor SS (2002) Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 115:3403-3414. (Pubitemid 34994030)
19. Ashar HR, et al. (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457.
20. Goodman B, et al. (2010) Lamin B counteracts the kinesin Eg5 to restrain spindle pole separation during spindle assembly. J Biol Chem 285:35238-35244.
21. Tsai MY, et al. (2006) A mitotic lamin B matrix induced by RanGTP required for spindle assembly. Science 311:1887-1893.
22. Fong LG, et al. (2006) Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 116:743-752. (Pubitemid 43326883)
23. Davies BS, et al. (2010) An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 19:2682-2694.
24. Sebti SM, Der CJ (2003) Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3:945-951.
25. Hougland JL, et al. (2010) Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. J Mol Biol 395:176-190.
26. Maurer-Stroh S, et al. (2007) Towards complete sets of farnesylated and geranylgeranylated proteins. PLOS Comput Biol 3:e66.
27. Crespo NC, et al. (2002) The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ 9:702-709. (Pubitemid 34778036)
28. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM (2001) The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167.
29. Kim J, et al. (2008) Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res 68:6831-6839.
30. Zhou J, et al. (2009) The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem 284:9648-9655.
31. Efuet ET, Keyomarsi K (2006) Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res 66:1040-1051. (Pubitemid 43165972)
32. Yang SH, Andres DA, Spielmann HP, Young SG, Fong LG (2008) Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest 118: 3291-3300.
33. Meta M, Yang SH, Bergo MO, Fong LG, Young SG (2006) Protein farnesyltransferase inhibitors and progeria. Trends Mol Med 12:480-487. (Pubitemid 44468196)
34. Lamson M, et al. (2002) Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos 23:143-149. (Pubitemid 34578273)
35. Verstraeten VL, Ji JY, Cummings KS, Lee RT, Lammerding J (2008) Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: Effects of farnesyltransferase inhibitors. Aging Cell 7:383-393. (Pubitemid 351663907)